The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long ...

With millions of people using injectable GLP-1 medications like Ozempic, Wegovy or Zepbound, many may wonder what happens if they stop. Previous clinical trials suggested a discouraging "rebound" ...

GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long-term safety, side effects, and global accessibility. Researchers stress ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today that its investigational drug retatrutide met primary and key secondary endpoints in a Phase 3 trial for type 2 diabetes treatment. The ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive the stock down by more than 50% despite the biotech hailing the data as ...

March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a significant reduction in blood sugar levels and weight in a late-stage trial, the company said on Thursday, as it looks to widen ...

Wegovy (semaglutide) is a medicine used to help people lose weight and keep it off. It belongs to a group of drugs called glucagon-like peptide-1s (GLP-1s). If you have heart disease and are ...

Ozempic, a type 2 diabetes treatment, presents investment opportunities via Novo Nordisk stock. Projected GLP-1 market growth to almost $160 billion by early the 2030s indicates long-term sector ...

Meaghan is an editor and writer who also has experience practicing holistic medicine as an acupuncturist and herbalist. She’s passionate about helping individuals live full, healthy and happy lives at ...